A randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial to evaluate the efficacy, safety, tolerability and pharmscokinetics of HZN-825 in patients with Diffuse Cutaneous Systemic Sclerosis
Clinical Trial Grant
Administered By
Medicine, Rheumatology and Immunology
Awarded By
Horizon Therapeutics Ireland DAC
Start Date
August 24, 2022
End Date
July 15, 2025
Administered By
Medicine, Rheumatology and Immunology
Awarded By
Horizon Therapeutics Ireland DAC
Start Date
August 24, 2022
End Date
July 15, 2025